
Andreas Goebel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4197970/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain, 2019, 160, 28-37.	4.2	645
2	Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain, 2011, 152, 2690-2700.	4.2	160
3	Intravenous Immunoglobulin Treatment of the Complex Regional Pain Syndrome. Annals of Internal Medicine, 2010, 152, 152.	3.9	155
4	Complex regional pain syndrome in adults. Rheumatology, 2011, 50, 1739-1750.	1.9	142
5	Complex regional pain syndrome — phenotypic characteristics and potential biomarkers. Nature Reviews Neurology, 2018, 14, 272-284.	10.1	132
6	A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Seminars in Arthritis and Rheumatism, 2019, 48, 933-940.	3.4	128
7	Passive transfer of fibromyalgia symptoms from patients to mice. Journal of Clinical Investigation, 2021, 131, .	8.2	106
8	Complex regional pain syndrome in adults: concise guidance. Clinical Medicine, 2011, 11, 596-600.	1.9	99
9	Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmunity Reviews, 2013, 12, 682-686.	5.8	96
10	A CRPS-IgG-transfer-trauma model reproducing inflammatory and positive sensory signs associated with complex regional pain syndrome. Pain, 2014, 155, 299-308.	4.2	79
11	Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors. Pain, 2014, 155, 2408-2417.	4.2	70
12	Standards for the diagnosis and management of complex regional pain syndrome: Results of a European Pain Federation task force. European Journal of Pain, 2019, 23, 641-651.	2.8	70
13	Transfer of complex regional pain syndrome to mice via human autoantibodies is mediated by interleukin-1–induced mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13067-13076.	7.1	66
14	The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria. Pain, 2021, 162, 2346-2348.	4.2	66
15	Human Pooled Immunoglobulin in the Treatment of Chronic Pain Syndromes. Pain Medicine, 2002, 3, 119-127.	1.9	60
16	Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition. Pain Medicine, 2022, 23, S1-S53.	1.9	50
17	Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Annals of Neurology, 2005, 57, 463-464.	5.3	48
18	Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. Journal of Neuroimmunology, 2005, 162, 184-189.	2.3	43

ANDREAS GOEBEL

#	Article	IF	CITATIONS
19	Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome. Annals of Internal Medicine, 2017, 167, 476.	3.9	43
20	Autoantibodies produce pain in complex regional pain syndrome by sensitizing nociceptors. Pain, 2019, 160, 2855-2865.	4.2	41
21	Plasma Exchange Therapy in Patients with Complex Regional Pain Syndrome. Pain Physician, 2015, 18, 383-94.	0.4	37
22	Dermal nerve fibre and mast cell density, and proximity of mast cells to nerve fibres in the skin of patients with complex regional pain syndrome. Pain, 2018, 159, 2021-2029.	4.2	28
23	The passive transfer of immunoglobulin G serum antibodies from patients with longstanding Complex Regional Pain Syndrome. European Journal of Pain, 2011, 15, 504.e1-504.e6.	2.8	27
24	Establishing the characteristics for patients with chronic Complex Regional Pain Syndrome: the value of the CRPS-UK Registry. British Journal of Pain, 2015, 9, 122-128.	1.5	27
25	Complex regional pain syndrome patient immunoglobulin M has pronociceptive effects in the skin and spinal cord of tibia fracture mice. Pain, 2020, 161, 797-809.	4.2	27
26	Placebo Responses in Long-Standing Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis. Journal of Pain, 2015, 16, 99-115.	1.4	25
27	Autoantibody pain. Autoimmunity Reviews, 2016, 15, 552-557.	5.8	24
28	Immunoglobulin Responsive Chronic Pain. Journal of Clinical Immunology, 2010, 30, 103-108.	3.8	23
29	Treatment of Long-Standing Complex Regional Pain Syndrome with Therapeutic Plasma Exchange: A Preliminary Case Series of Patients Treated in 2008–2014. Pain Medicine, 2014, 15, 2163-2164.	1.9	23
30	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	1.9	22
31	The autoimmune aetiology of unexplained chronic pain. Autoimmunity Reviews, 2022, 21, 103015.	5.8	18
32	Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (LIPS): study protocol for a randomized controlled trial. Trials, 2014, 15, 404.	1.6	17
33	Dorsal Root Ganglion Stimulation for Complex Regional Pain Syndrome (CRPS) Recurrence after Amputation for CRPS, and Failure of Conventional Spinal Cord Stimulation. Pain Practice, 2018, 18, 104-108.	1.9	17
34	Disputing space-based biases in unilateral complex regional pain syndrome. Cortex, 2020, 127, 248-268.	2.4	17
35	Complex regional pain syndrome what is the outcome? ―a systematic review of the course and impact of CRPS at 12 months from symptom onset and beyond. European Journal of Pain, 2022, 26, 1203-1220.	2.8	15
36	Widespread Pain in Patients with Complex Regional Pain Syndrome. Pain Practice, 2014, 14, 526-531.	1.9	13

ANDREAS GOEBEL

#	Article	IF	CITATIONS
37	A Systematic Review Into the Influence of Temperature on Fibromyalgia Pain: Meteorological Studies and Quantitative Sensory Testing. Journal of Pain, 2021, 22, 473-486.	1.4	13
38	Mycophenolate for persistent complex regional pain syndrome, a parallel, open, randomised, proof of concept trial. Scandinavian Journal of Pain, 2018, 18, 29-37.	1.3	12
39	Prism adaptation treatment for upper-limb complex regional pain syndrome: a double-blind randomized controlled trial. Pain, 2021, 162, 471-489.	4.2	12
40	Immunoglobulin maintenance therapy in long-standing complex regional pain syndrome, an open study. Rheumatology, 2013, 52, 2091-2093.	1.9	10
41	Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: a study protocol[ISRCTN33042138]. BMC Neurology, 2003, 3, 1.	1.8	9
42	Current Concepts in Adult CRPS. Reviews in Pain, 2011, 5, 3-11.	0.1	9
43	Randomised controlled trial to investigate the effectiveness of thoracic epidural and paravertebral blockade in reducing chronic post-thoracotomy pain (TOPIC): a pilot study to assess feasibility of a large multicentre trial. BMJ Open, 2019, 9, e023679.	1.9	9
44	A randomised placebo-controlled Phase III multicentre trial: low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome (LIPS trial). Efficacy and Mechanism Evaluation, 2017, 4, 1-82.	0.7	9
45	Discovery of novel targets in a complex regional pain syndrome mouse model by transcriptomics: TNF and JAK-STAT pathways. Pharmacological Research, 2022, 182, 106347.	7.1	9
46	Buprenorphine injection to the stellate ganglion in the treatment of upper body chronic pain syndromes. European Journal of Pain, 2008, 12, 266-274.	2.8	8
47	Management of adult patients with long-standing complex regional pain syndrome. Pain Management, 2013, 3, 137-146.	1.5	8
48	Effects of serum immunoglobulins from patients with complex regional pain syndrome (CRPS) on depolarisation-induced calcium transients in isolated dorsal root ganglion (DRG) neurons. Experimental Neurology, 2016, 277, 96-102.	4.1	6
49	Diagnosis of chronic primary pain in the context of structural deformity needs better definition. Pain, 2021, 162, 320-320.	4.2	5
50	Research Recommendations Following the Discovery of Pain Sensitizing IgG Autoantibodies in Fibromyalgia Syndrome. Pain Medicine, 2022, 23, 1084-1094.	1.9	4
51	Complex regional pain syndrome (CRPS) in orthopaedics: an overview. Orthopaedics and Trauma, 2019, 33, 217-223.	0.4	3
52	A technique to assess perineuronal mediators. British Journal of Neurosurgery, 2018, 32, 697-699.	0.8	2
53	Delayed onset of severe chronic pain in CASPR2 autoantibody–associated Morvan syndrome in a former UK swine abattoir worker. Pain Reports, 2018, 3, e675.	2.7	2
54	Patient consultation about a trial of therapeutic plasma exchange for complex regional pain syndrome. Journal of Clinical Apheresis, 2018, 33, 661-665.	1.3	2

ANDREAS GOEBEL

#	Article	IF	CITATIONS
55	Exploring the impact of pain management programme attendance on complex regional pain syndrome (CRPS) patients' decision making regarding immunosuppressant treatment to manage their chronic pain condition. Scandinavian Journal of Pain, 2020, 20, 707-716.	1.3	2
56	Aftersensations and Lingering Pain After Examination in Patients with Fibromyalgia Syndrome. Pain Medicine, 2022, 23, 1928-1938.	1.9	2
57	Anesthesiologists' Views on Using Immune Modulating Drugs in Pain Medicine. Pain Practice, 2011, 11, 344-352.	1.9	1
58	Complex regional pain syndrome: developing diagnostic tools and treatments from sympathetic nervous system, neuroimmune and neuromodulation discoveries in neuropathic pain. Regional Anesthesia and Pain Medicine, 2021, 46, 193-195.	2.3	1
59	Unexplained Nausea and Weight Loss in Two Cases of Longstanding CRPS. Pain Medicine, 2013, 14, 1806-1807.	1.9	0
60	I66. Complex Regional Pain Syndrome: The UK Guidance, and Current and Future Management. Rheumatology, 2014, 53, i14-i14.	1.9	0